Media

November 14, 2022

Organon Canada launches ONTRUZANT®, a biosimilar of the reference biologic Herceptin, providing patients in Canada with certain breast and gastric cancers with an additional therapeutic option at a lower cost

November 7, 2022

Organon Canada launches AYBINTIO®, a biosimilar of the reference biologic Avastin, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer

September 26, 2022

On World Contraception Day, Organon wants to help tackle the global issue of unintended pregnancies by helping ensure women make informed decisions about their reproductive health

July 28, 2022

Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate

June 17, 2022

This World Infertility Awareness Month, Organon Canada is committed to listening and highlighting different paths and barriers to parenthood

June 13, 2022

Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates

June 2, 2022

Organon Introduces Global Environmental, Social and Governance (ESG) Strategy and Commitments with Publication of Inaugural ESG Report

May 25, 2022

PROMETRIUM^® and ESTROGEL^® now covered without any conditions by Quebec’s public formulary

February 2, 2022

Organon Canada declares paid time off for all employees on International Women’s Day.

January 11, 2022

NEXPLANON^® now covered by Ontario,  British Columbia and Nova Scotia’s public formularies

November 8, 2021

NEXPLANON^® now covered by Quebec’s public formulary

September 22, 2021

Organon wants to help women take control of their birth control

June 21, 2021

Organon Canada Launches as New Women’s Health Company

For media related inquiries about Organon Canada or our products,
please contact our Media Centre at:

1-450-366-1740
media_canada@organon.com